文献速递糖尿病

糖尿病心血管自主神经病变:以管理为重点的更新

Cardiovascular autonomic neuropathy in diabetes: an update with a focus on management.
PubMed 文献 · Diabetologia · 2024-08-09

本文综述糖尿病心血管自主神经病变(CAN)的近期进展,指出CAN影响约20%的糖尿病患者,也见于糖尿病前期; wearable设备和心率变异性监测可简化早期检测;SGLT2抑制剂和GLP-1受体激动剂等新型降糖药可能带来有利影响;强调识别和管理这一被低估的并发症。

要点

  • CAN影响约20%的糖尿病患者,糖尿病前期(糖耐量受损和/或空腹血糖受损)中也存在CAN。
  • 可穿戴设备和心率变异性监测为CAN早期检测提供简化且具成本效益的方法。
  • SGLT2抑制剂和GLP-1受体激动剂等新型降糖药可能对CAN有有利影响。

核心结论

  • CAN是一种被低估但高流行的糖尿病微血管并发症,显著增加糖尿病患者心血管事件和死亡风险;本综述重点提供识别和管理这一诊断不足状况的实用指导。

研究设计与样本

  • 本文为综述,围绕糖尿病心血管自主神经病变(CAN)的近期进展展开,重点涉及管理方面的实用指导。

主要发现

  • CAN影响约20%的糖尿病患者,近期研究强调糖尿病前期(糖耐量受损和/或空腹血糖受损)中也存在CAN。
  • 新出现的证据支持脂质代谢物、线粒体功能障碍和遗传学之间可能存在联系。
  • 通过可穿戴设备和心率变异性监测可简化CAN检测,提供简化且具成本效益的早期CAN检测方法;需进一步研究如何最佳利用此类设备提供的大量数据。
  • 尽管缺乏针对自主神经病变潜在病理生理的特异性药物干预,一些研究提示新型降糖药如SGLT2抑制剂和GLP-1受体激动剂有有利影响,这些药物已有大量预防心血管事件的临床试验数据。

临床怎么用

  • 本综述强调提供实用指导以识别和管理CAN这一诊断不足的状况,该状况显著增加糖尿病患者心血管事件和死亡风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cardiovascular autonomic neuropathy (CAN) is an under-recognised yet highly prevalent microvascular complication of diabetes. CAN affects approximately 20% of people with diabetes, with recent studies highlighting the presence of CAN in prediabetes (impaired glucose tolerance and/or impaired fasting glucose), indicating early involvement of the autonomic nervous system. Understanding of the pathophysiology of CAN continues to evolve, with emerging evidence supporting a potential link between lipid metabolites, mitochondrial dysfunction and genetics. Recent advancements, such as streamlining CAN detection through wearable devices and monitoring of heart rate variability, present simplified and cost-effective approaches for early CAN detection. Further research on the optimal use of the extensive data provided by such devices is required. Despite the lack of specific pharmacological interventions targeting the underlying pathophysiology of autonomic neuropathy, several studies have suggested a favourable impact of newer glucose-lowering agents, such as sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists, where there is a wealth of clinical trial data on the prevention of cardiovascular events. This review delves into recent developments in the area of CAN, with emphasis on practical guidance to recognise and manage this underdiagnosed condition, which significantly increases the risk of cardiovascular events and mortality in diabetes.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Eleftheriadou A, Spallone V, Tahrani AA, et al. Cardiovascular autonomic neuropathy in diabetes: an update with a focus on management. Diabetologia. 2024. PMID: 39120767. doi:10.1007/s00125-024-06242-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。